Helen Torley
Chief Executive Officer at HALOZYME THERAPEUTICS, INC.
Net worth: 28 M $ as of 2024-03-30
Profile
Helen I. Torley occupies the position of President, Chief Executive Officer & Director at Halozyme Therapeutics, Inc. She is also on the board of Quest Diagnostics, Inc. and Director & Member-Health Section Governing Board at Biotechnology Innovation Organization and Member of The Royal College of Physicians. In the past she was Vice President & GM-United States Bone Health at Amgen, Inc. and Chief Commercial Officer & Executive VP for Onyx Pharmaceuticals, Inc. (a subsidiary of Amgen, Inc.), Vice President-Medical Affairs of Novartis, Inc., Vice President-Medical Affairs for Sandoz SA and Vice President-Cardiovascular & Metabolic Sales at Bristol-Myers Squibb World Wide Medicines Group. She received an undergraduate degree from the University of Glasgow.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2024-02-25 | 676,744 ( 0.53% ) | 28 M $ | 2024-03-30 |
Helen Torley active positions
| Companies | Position | Start |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Chief Executive Officer | 2014-01-05 |
| ANTARES PHARMA, INC. | Director/Board Member | 2022-05-23 |
| The Royal College of Physicians | Corporate Officer/Principal | - |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Director/Board Member | - |
Former positions of Helen Torley
| Companies | Position | End |
|---|---|---|
| QUEST DIAGNOSTICS INCORPORATED | Director/Board Member | 2022-05-17 |
| RELYPSA INC | Director/Board Member | 2016-08-31 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Chief Operating Officer | 2011-12-14 |
| AMGEN INC. | Corporate Officer/Principal | 2010-12-31 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | 2001-12-31 |
Training of Helen Torley
| University of Glasgow | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 4 |
|---|---|
| AMGEN INC. | Health Technology |
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| QUEST DIAGNOSTICS INCORPORATED | Health Services |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| Private companies | 6 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
Antares Pharma, Inc.
 Antares Pharma, Inc. Pharmaceuticals: MajorHealth Technology Antares Pharma, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and technologies in targeted therapeutic areas. Its products include XYOSTED injection, OTREXUP injection for subcutaneous use, and Sumatriptan injection. The company was founded in February 1979 and is headquartered in Ewing, NJ. | Health Technology |
Novartis, Inc.
 Novartis, Inc. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis, Inc. is a private company based in San Francisco. | Health Technology |
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Commercial Services |
Relypsa, Inc.
 Relypsa, Inc. Pharmaceuticals: MajorHealth Technology Relypsa, Inc. operates as a bio-pharmaceutical company, which engages in the development and commercialization of late-stage medicines in the iron deficiency, nephrology, and cardio-renal therapeutic areas. It offers Veltassa, a potassium binder approved for the treatment of hyperkalemia. The company was founded by Jerry M. Buysse, Gerrit Klaerner, Michael Burdick, Jay P. Shepard, Detlef F. Albrecht, George Tyson, Sandra I. Coufal and Vic Ciaravino on October 29, 2007 and is headquartered in Redwood City, CA. | Health Technology |
| Sandoz SA |
- Stock Market
- Insiders
- Helen Torley
